Eusa Pharma to acquire Cytogen

Under the terms of the all-cash merger agreement Cytogen shareholders will receive $0.62 per share, representing a 35% premium on the company’s share price. To meet the acquisition consideration, and fund further investments, Eusa Pharma has concurrently raised over $50 million in an investment round, led by TVM Capital, an international venture capital firm.

Rolf Stahel, chairman of Eusa Pharma, said: “This transaction will transform our business, putting in place a truly transatlantic growth platform, and positioning the company as the partner of choice for future acquisitions and specialty product in-licensing.”